Callan JMB Inc. Launches Subsidiary in India and Progresses to Establish Temperature-Controlled Warehouse
Callan JMB (NASDAQ: CJMB) has established a new subsidiary, Callan JMB Services (India) Private Limited, to expand its logistics services in India. The company plans to open a temperature-controlled warehouse in Pune, Maharashtra capable of storing pharmaceuticals at various temperatures, including -80°C for tissue samples.
The subsidiary, incorporated on June 20, 2025, will facilitate pharmaceutical distribution within India and help Indian companies establish manufacturing operations in the U.S. The company has already secured an agreement with Walker's Pharmaceuticals and is collaborating with Brihans Natural Products for U.S. manufacturing setup and distribution services.
Callan JMB (NASDAQ: CJMB) ha creato una nuova filiale, Callan JMB Services (India) Private Limited, per espandere i suoi servizi logistici in India. L'azienda prevede di aprire un magazzino a temperatura controllata a Pune, Maharashtra, in grado di conservare prodotti farmaceutici a diverse temperature, incluso a -80°C per campioni di tessuto.
La filiale, costituita il 20 giugno 2025, faciliterà la distribuzione farmaceutica all'interno dell'India e aiuterà le aziende indiane a stabilire operazioni produttive negli Stati Uniti. La società ha già siglato un accordo con Walker's Pharmaceuticals e collabora con Brihans Natural Products per l'allestimento della produzione e i servizi di distribuzione negli USA.
Callan JMB (NASDAQ: CJMB) ha establecido una nueva subsidiaria, Callan JMB Services (India) Private Limited, para expandir sus servicios logísticos en India. La empresa planea abrir un almacén con temperatura controlada en Pune, Maharashtra, capaz de almacenar productos farmacéuticos a diversas temperaturas, incluyendo -80°C para muestras de tejido.
La subsidiaria, constituida el 20 de junio de 2025, facilitará la distribución farmacéutica dentro de India y ayudará a las empresas indias a establecer operaciones de fabricación en EE. UU. La compañía ya ha asegurado un acuerdo con Walker's Pharmaceuticals y está colaborando con Brihans Natural Products para la instalación de fabricación y servicios de distribución en EE. UU.
Callan JMB (NASDAQ: CJMB)는 인도 내 물류 서비스를 확장하기 위해 새로운 자회사인 Callan JMB Services (India) Private Limited를 설립했습니다. 회사는 마하라슈트라주 푸네에 온도 조절 창고를 열 계획이며, 조직 샘플을 위한 -80°C를 포함한 다양한 온도에서 의약품을 보관할 수 있습니다.
2025년 6월 20일에 설립된 이 자회사는 인도 내 의약품 유통을 지원하고 인도 기업들이 미국에 제조 시설을 설립하는 데 도움을 줄 것입니다. 회사는 이미 Walker's Pharmaceuticals와 계약을 체결했으며, Brihans Natural Products와 미국 내 제조 및 유통 서비스 협력을 진행 중입니다.
Callan JMB (NASDAQ : CJMB) a créé une nouvelle filiale, Callan JMB Services (India) Private Limited, afin d'étendre ses services logistiques en Inde. La société prévoit d'ouvrir un entrepôt à température contrôlée à Pune, Maharashtra, capable de stocker des produits pharmaceutiques à différentes températures, y compris à -80°C pour des échantillons de tissus.
La filiale, constituée le 20 juin 2025, facilitera la distribution pharmaceutique en Inde et aidera les entreprises indiennes à établir des opérations de fabrication aux États-Unis. La société a déjà conclu un accord avec Walker's Pharmaceuticals et collabore avec Brihans Natural Products pour la mise en place de la production et des services de distribution aux États-Unis.
Callan JMB (NASDAQ: CJMB) hat eine neue Tochtergesellschaft, Callan JMB Services (India) Private Limited, gegründet, um seine Logistikdienstleistungen in Indien auszubauen. Das Unternehmen plant die Eröffnung eines temperaturkontrollierten Lagers in Pune, Maharashtra, das pharmazeutische Produkte bei verschiedenen Temperaturen lagern kann, einschließlich -80°C für Gewebeproben.
Die Tochtergesellschaft, gegründet am 20. Juni 2025, wird den pharmazeutischen Vertrieb innerhalb Indiens erleichtern und indischen Unternehmen helfen, Produktionsstätten in den USA aufzubauen. Das Unternehmen hat bereits eine Vereinbarung mit Walker's Pharmaceuticals abgeschlossen und arbeitet mit Brihans Natural Products bei der Einrichtung der US-Produktion und Vertriebsdiensten zusammen.
- Strategic expansion into Indian market through new subsidiary establishment
- Secured partnership with Walker's Pharmaceuticals and potential deal with Brihans Natural Products
- Leveraging existing expertise in cold chain logistics and tissue sample transportation
- Diversification of services to include helping Indian companies establish U.S. manufacturing
- Significant capital investment required for temperature-controlled warehouse infrastructure
- Potential regulatory complexities in both Indian and U.S. markets
Insights
Callan JMB's strategic India expansion strengthens its pharmaceutical cold-chain capabilities while creating bidirectional US-India market access opportunities.
Callan JMB's formation of an Indian subsidiary represents a calculated expansion of its specialized pharmaceutical logistics footprint into a high-growth market. The company is leveraging its existing experience shipping tissue samples from India to establish a comprehensive local operation including a temperature-controlled facility in Pune capable of handling extreme cold storage requirements down to -80°C.
This move offers three distinct value propositions: First, it enhances the company's clinical trial logistics capabilities by streamlining processes and reducing costs for tissue sample transportation. Second, it positions Callan JMB as an import facilitator for Active Pharmaceutical Ingredients (APIs) and wellness products from India to the US market. Third, and perhaps most strategically valuable, it establishes the company as a consultant helping Indian manufacturers navigate US market entry requirements, including pharmaceutical compliance.
The subsidiary has already secured agreements with Walker's Pharmaceuticals and is working with Brihans Natural Products to assist both companies in establishing US manufacturing plants, demonstrating immediate commercial traction. This bidirectional approach—facilitating both Indian companies' US entry and US companies' access to Indian markets—creates a unique competitive position within the specialized healthcare logistics space.
The timing aligns with increased pharmaceutical supply chain diversification efforts and growing clinical trial activity in India. By offering specialized cold chain infrastructure required for tissue sample preservation, Callan JMB addresses a critical logistics gap that mainstream carriers struggle to service consistently. The company's emphasis on regulatory compliance expertise represents a valuable differentiator when helping foreign manufacturers navigate the complex US pharmaceutical market entry requirements.
Callan JMB Services (India) Private Limited to offer logistics services in India, with a planned warehouse in Pune, Maharashtra for storage and distribution of pharmaceuticals at all temperature ranges
SPRING BRANCH, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has formed Callan JMB Services (India) Private Limited to offer logistics services in India. The subsidiary has a management office and will soon have an operational warehouse in Pune, Maharashtra, India for storage and distribution of pharmaceuticals at all temperature ranges, including -80○C, needed for storing tissue samples for clinical trials.
On June 20, 2025, Callan JMB incorporated its India business subsidiary, Callan JMB Services (India) Private Limited, to distribute pharmaceutical and wellness products within India. In addition, the U.S. Callan JMB Services (India) Private Limited will also assist Indian companies in establishing onshore manufacturing plants in the U.S. The newly incorporated company already has an agreement with Walker’s Pharmaceuticals Ltd. and is working with Brihans Natural Products Ltd. to assist both companies in establishing U.S. manufacturing plants, acting as distributors of their products in the U.S.
“Our successful track record of shipping tissue samples from India to the U.S. for clinical trials demonstrated the need for dedicated operations in India to streamline the process and reduce costs,” said Wayne Williams, Founder and CEO of Callan JMB. “We bring specialized cold chain logistics expertise that enables Indian companies to efficiently navigate the complexities of establishing operations and distribution in the U.S. market.”
Callan JMB is uniquely positioned to import tissue samples for clinical trials and active pharmaceutical ingredients (APIs), in addition to wellness products made in India. These life-changing imports will help develop new pharmaceuticals and alleviate drug shortages in the U.S. Callan JMB’s extensive knowledge of pharmaceutical compliance is a key service to companies wanting to expand into the U.S. manufacturing sector, and its cold chain distribution system will reach the Indian market reliably and safely.
About Callan JMB
Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge on the SEC's website at: http://www.sec.gov. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, and disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Company hereafter becomes aware.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
FAQ
What is the purpose of Callan JMB's new Indian subsidiary?
Where will CJMB's new temperature-controlled warehouse be located?
Which Indian companies is Callan JMB (CJMB) partnering with?
When was Callan JMB Services India Private Limited incorporated?
What temperature capabilities will CJMB's new warehouse facility have?
